KEYS vs REGN · P/E 57, rev $4.98B vs P/E 14, rev $14.34B
Keysight Technologies Inc (KEYS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
KEYS currently screens at market cap $59.84B and trailing P/E 56.5. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the KEYS and REGN stock pages for the full models.
Not investment advice.